Core Insights - Olympus Corporation has committed $150 million to establish OIV Fund II, targeting investments in promising medtech startups within the gastrointestinal, urology, and respiratory sectors [1] - The fund is described as 'stage-agnostic', focusing on early to growth-stage companies globally that offer therapeutic solutions for specific medical specialties [2] - OIV Fund I, the inaugural fund, had a capital allocation of $50 million and invested in nine medtech startups, including On Target Laboratories and Universal Diagnostics [3] Investment Strategy - OIV Fund II aims to create a pipeline of M&A opportunities, partnerships, and valuable market insights [1] - The fund will continue to support existing portfolio companies from OIV Fund I, which was launched in 2021 [2] - Olympus's chief strategy officer emphasized the commitment to investing in startup teams developing unique solutions in endoscopy-enabled care [4] Management and Partnerships - Cerity Partners Ventures will continue to manage OIV's second fund, having partnered with Olympus since the launch of the first fund [4] - The collaboration aims to leverage technical strengths, industry relationships, and expertise to support leading entrepreneurs [5] Market Positioning - Olympus is focusing on carving out a position in the market with its investments in GI startups, including the establishment of Swan EndoSurgical Robotics, which aims to develop an endoluminal surgical robotics platform [5][6] - Swan's goal is to enhance minimally invasive treatment options for GI tract lesions or tumors by addressing ergonomic limitations of manual endoscopy [6]

David George is a General Partner at Andreessen Horowitz, where he leads the firm's Growth investing team. His team has backed many of the defining companies of this era, including Databricks, Figma, Stripe, SpaceX, Anduril, and OpenAI, and is now investing behind a new generation of AI startups like Cursor, Harvey, and Abridge. ----------------------------------------------- Timestamps: 00:00 Intro 01:24 Why Everyone is Wrong: Mega Funds Does Not Reduce Returns 07:13 The Biggest Advantage of Staying Privat ...

The best VCs don't try to run their portfolio companies, they clear the path for the next round and get out of your way.@fubini explains how @xyz_vc wins by bringing ecosystem expertise and network access while trusting founders to do what they do best...build.Listen to this week’s full episode of Build Mode, also featuring @lesliefeinzaig of @grahamandwalker: https://t.co/TQf6MzfrAn ...

The best VCs don't try to run their portfolio companies, they clear the path for the next round and get out of your way.@fubini explains how @xyz_vc wins by bringing ecosystem expertise and network access while trusting founders to do what they do best...build.Listen to this week’s full episode of Build Mode, also featuring @lesliefeinzaig of @grahamandwalker: https://t.co/TQf6MzfrAn ...

Most VCs have never raised a fund themselves. Leslie Feinzaig explains why GPs like her and Ross Fubini, who've been in founders' shoes, can better help their portfolio companies make smart partnership decisions.Listen to this week’s full episode of Build Mode with @lesliefeinzaig (@grahamandwalker), @fubini (@xyz_vc) and our host Isabelle Johannessen: https://t.co/TQf6MzfrAn ...

The best VCs don't try to run their portfolio companies, they clear the path for the next round and get out of your way.@fubini explains how @xyz_vc wins by bringing ecosystem expertise and network access while trusting founders to do what they do best...build.Listen to this week’s full episode of Build Mode, also featuring @lesliefeinzaig of @grahamandwalker: https://t.co/TQf6MzfrAn ...

Most VCs have never raised a fund themselves. Leslie Feinzaig explains why GPs like her and Ross Fubini, who've been in founders' shoes, can better help their portfolio companies make smart partnership decisions.Listen to this week’s full episode of Build Mode with @lesliefeinzaig (@grahamandwalker), @fubini (@xyz_vc) and our host Isabelle Johannessen: https://t.co/TQf6MzfrAn ...

The market has ‘switched’ and founders have the power now, VCs say https://t.co/k4caaid19X ...

Big exits and big raises have brought big changes to the ninth annual Midas List Europe, which ranks the top 25 startup investors in Europe and the Middle East.Leading the pack: Index Venture’s Danny Rimer returns to the top of the list after Figma finally went public with a $19 billion valuation in July.The initial public offerings of Klarna and BillionToOne, combined with billion-dollar fundraises from private startups like digital bank Revolut, French AI lab Mistral and defence startup Helsing, also drov ...

Partners Barend Van den Brande and Firat Ileri at low-profile London fund Hummingbird both won spots on the Midas List Europe for tearing up the venture rulebook and backing “outlier” founders. #ForbesMidas https://t.co/b5SP3vdzZ4 ...